All clinical trials must have a written Data and Safety Monitoring (DSM) plan. Many clinical trials activated at the Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) are multicenter trials and have a DSM plan that has been previously approved by an appropriate authority external to VCU. Although not required by NCI CCSG guidelines or NCI/NIH policy, the MCC default DSM plan for clinical trials is a DSMB. DSMBs evaluate ongoing trials for data integrity and subject safety. DSMB recommendations are reported to investigators and the IRB. If a DSMB identifies problems so serious as to raise doubts about the meaningfulness of the results of a trial, it also reports its findings to the Protocol Review and Monitoring Committee (PRMC). Although DSMBs make recommendations, the DSMB function is an advisory function. In addition to the DSMB, a DSM plan generally contains two other components: the Study Team and an Audit Committee (AC). The Study Team is the group primarily responsible for study conduct. In most cases, the study team consists of the Investigator(s), Study Biostatistician, a Research Nurse, a Clinical Research Associate, and a Regulatory Expert. Study teams meet regularly as appropriate for an individual study. ACs audit trials for regulatory compliance, protocol compliance, and data quality. AC findings are reported to the investigator and the trial DSMB. Although the AC may make recommendations, the AC function is a fact finding function.

Agency
National Institute of Health (NIH)
Type
Center Core Grants (P30)
Project #
5P30CA016059-33
Application #
8662714
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
33
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Virginia Commonwealth University
Department
Type
DUNS #
City
Richmond
State
VA
Country
United States
Zip Code
23298
Ginder, Gordon D (2015) Epigenetic regulation of fetal globin gene expression in adult erythroid cells. Transl Res 165:115-25
Chen, Shuang; Zhang, Yu; Zhou, Liang et al. (2014) A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 124:2687-97
Youniss, Fatma M; Sundaresan, Gobalakrishnan; Graham, Laura J et al. (2014) Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling. PLoS One 9:e109162
Teves, Maria E; Sears, Patrick R; Li, Wei et al. (2014) Sperm-associated antigen 6 (SPAG6) deficiency and defects in ciliogenesis and cilia function: polarity, density, and beat. PLoS One 9:e107271
Bie, Jinghua; Wang, Jing; Yuan, Quan et al. (2014) Liver-specific transgenic expression of cholesteryl ester hydrolase reduces atherosclerosis in Ldlr-/- mice. J Lipid Res 55:729-38
Teramachi, Jumpei; Zhou, Hua; Subler, Mark A et al. (2014) Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone. J Bone Miner Res 29:1456-65
Nakagawa, Akito; Lui, Francine E; Wassaf, Dina et al. (2014) Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chem Biol 9:2318-25
Sarkar, S; Azab, B; Quinn, B A et al. (2014) Chemoprevention gene therapy (CGT) of pancreatic cancer using perillyl alcohol and a novel chimeric serotype cancer terminator virus. Curr Mol Med 14:125-40
Dhall, Sandeep; Do, Danh; Garcia, Monika et al. (2014) A novel model of chronic wounds: importance of redox imbalance and biofilm-forming bacteria for establishment of chronicity. PLoS One 9:e109848
Rahmani, Mohamed; Aust, Mandy Mayo; Benson, Elisa C et al. (2014) PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res 20:4849-60

Showing the most recent 10 out of 215 publications